The CEO discusses the normalized demand environment in the US, emphasizing the essential role of flow cytometry in biology labs. The CFO expects sequential revenue growth in Q4 and outlines strategies for future profitability. The company plans new product launches and anticipates growth in the APAC region despite challenges in the market.